Stocks and Investing Stocks and Investing
Wed, January 8, 2014
Tue, January 7, 2014
Mon, January 6, 2014

Joel Beatty Downgraded (SRPT) to Strong Sell and Held Target at $13 on, Jan 6th, 2014


Published on 2024-10-25 03:57:49 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Citigroup, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Strong Sell and Held Target at $13 on, Jan 6th, 2014.

Joel has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Joseph Schwartz of "Leerink Swann" Maintained at Hold with Decreased Target to $17 on, Tuesday, November 12th, 2013


This is the rating of the analyst that currently disagrees with Joel


  • Yun Zhong of "Janney Montgomery Scott" Downgraded from Hold to Strong Sell and Decreased Target to $10 on, Tuesday, November 12th, 2013
Contributing Sources